Dry, arid and remote farming regions are vulnerable to water shortages, but scientists are working on a promising new solution.
As scientists have searched for solutions, an alternative water supply has been hiding in plain sight: Water vapor in the atmosphere. It is abundant, available, and endlessly renewable, just waiting for the moment that technological innovation and necessity converged to make it fit for use. Now, new super-moisture-absorbent gels developed by Yu and a team of researchers can pull that moisture from the air and bring it into soil, potentially expanding the map of farmable land around the globe to dry and remote regions that suffer from water shortages.
"This opens up opportunities to turn those previously poor-quality or inhospitable lands to become useable and without need of centralized water and power supplies," Yu said.
A renewable source of freshwater
The hydrogels are a gelatin-like substance made from synthetic materials. The gels activate in cooler, humid overnight periods and draw water from the air. During a four-week experiment, Yu's team observed that soil with these gels provided enough water to support seed germination and plant growth without an additional liquid water supply. And the soil was able to maintain the moist environment for more than a month, according to Yu.
The super absorbent gels developed at the University of Texas at Austin.
Xingyi Zhou, UT Austin
"It is promising to liberate underdeveloped and drought areas from the long-distance water and power supplies for agricultural production," Yu said.
Crops also rely on fertilizer to maintain soil fertility and increase the production yield, but it is easily lost through leaching. Runoff increases agricultural costs and contributes to environmental pollution. The interaction between the gels and agrochemicals offer slow and controlled fertilizer release to maintain the balance between the root of the plant and the soil.
The possibilities are endless
Harvesting atmospheric water is exciting on multiple fronts. The super-moisture-absorbent gel can also be used for passively cooling solar panels. Solar radiation is the magic behind the process. Overnight, as temperatures cool, the gels absorb water hanging in the atmosphere. The moisture is stored inside the gels until the thermometer rises. Heat from the sun serves as the faucet that turns the gels on so they can release the stored water and cool down the panels. Effective cooling of the solar panels is important for sustainable long-term power generation.
In addition to agricultural uses and cooling for energy devices, atmospheric water harvesting technologies could even reach people's homes.
"They could be developed to enable easy access to drinking water through individual systems for household usage," Yu said.
Next steps
Yu and the team are now focused on affordability and developing practical applications for use. The goal is to optimize the gel materials to achieve higher levels of water uptake from the atmosphere.
"We are exploring different kinds of polymers and solar absorbers while exploring low-cost raw materials for production," Yu said.
The ability to transform atmospheric water vapor into a cheap and plentiful water source would be a game-changer. One day in the not-too-distant future, if climate change intensifies and droughts worsen, this innovation may become vital to our very survival.
Marielle Gross, a professor at the University of Pittsburgh, shows patients a new app that tracks how their samples are used during biomedical research.
Tissue donors can track what scientists do with their samples while safeguarding privacy, through a pilot program initiated in October by researchers at the Johns Hopkins Berman Institute of Bioethics and the University of Pittsburgh’s Institute for Precision Medicine. The program uses blockchain technology to offer patients this opportunity through the University of Pittsburgh's Breast Disease Research Repository, while assuring that their identities remain anonymous to investigators.
A blockchain is a digital, tamper-proof ledger of transactions duplicated and distributed across a computer system network. Whenever a transaction occurs with a patient’s sample, multiple stakeholders can track it while the owner’s identity remains encrypted. Special certificates called “nonfungible tokens,” or NFTs, represent patients’ unique samples on a trusted and widely used blockchain that reinforces transparency.
Blockchain could be used to notify people if cancer researchers discover that they have certain risk factors.
“Healthcare is very data rich, but control of that data often does not lie with the patient,” said Julius Bogdan, vice president of analytics for North America at the Healthcare Information and Management Systems Society (HIMSS), a Chicago-based global technology nonprofit. “NFTs allow for the encapsulation of a patient’s data in a digital asset controlled by the patient.” He added that this technology enables a more secure and informed method of participating in clinical and research trials.
Without this technology, de-identification of patients’ samples during biomedical research had the unintended consequence of preventing them from discovering what researchers find -- even if that data could benefit their health. A solution was urgently needed, said Marielle Gross, assistant professor of obstetrics, gynecology and reproductive science and bioethics at the University of Pittsburgh School of Medicine.
“A researcher can learn something from your bio samples or medical records that could be life-saving information for you, and they have no way to let you or your doctor know,” said Gross, who is also an affiliate assistant professor at the Berman Institute. “There’s no good reason for that to stay the way that it is.”
For instance, blockchain could be used to notify people if cancer researchers discover that they have certain risk factors. Gross estimated that less than half of breast cancer patients are tested for mutations in BRCA1 and BRCA2 — tumor suppressor genes that are important in combating cancer. With normal function, these genes help prevent breast, ovarian and other cells from proliferating in an uncontrolled manner. If researchers find mutations, it’s relevant for a patient’s and family’s follow-up care — and that’s a prime example of how this newly designed app could play a life-saving role, she said.
Liz Burton was one of the first patients at the University of Pittsburgh to opt for the app -- called de-bi, which is short for decentralized biobank -- before undergoing a mastectomy for early-stage breast cancer in November, after it was diagnosed on a routine mammogram. She often takes part in medical research and looks forward to tracking her tissues.
“Anytime there’s a scientific experiment or study, I’m quick to participate -- to advance my own wellness as well as knowledge in general,” said Burton, 49, a life insurance service representative who lives in Carnegie, Pa. “It’s my way of contributing.”
Liz Burton was one of the first patients at the University of Pittsburgh to opt for the app before undergoing a mastectomy for early-stage breast cancer.
Liz Burton
The pilot program raises the issue of what investigators may owe study participants, especially since certain populations, such as Black and indigenous peoples, historically were not treated in an ethical manner for scientific purposes. “It’s a truly laudable effort,” Tamar Schiff, a postdoctoral fellow in medical ethics at New York University’s Grossman School of Medicine, said of the endeavor. “Research participants are beautifully altruistic.”
Lauren Sankary, a bioethicist and associate director of the neuroethics program at Cleveland Clinic, agrees that the pilot program provides increased transparency for study participants regarding how scientists use their tissues while acknowledging individuals’ contributions to research.
However, she added, “it may require researchers to develop a process for ongoing communication to be responsive to additional input from research participants.”
Peter H. Schwartz, professor of medicine and director of Indiana University’s Center for Bioethics in Indianapolis, said the program is promising, but he wonders what will happen if a patient has concerns about a particular research project involving their tissues.
“I can imagine a situation where a patient objects to their sample being used for some disease they’ve never heard about, or which carries some kind of stigma like a mental illness,” Schwartz said, noting that researchers would have to evaluate how to react. “There’s no simple answer to those questions, but the technology has to be assessed with an eye to the problems it could raise.”
To truly make a difference, blockchain must enable broad consent from patients, not just de-identification.
As a result, researchers may need to factor in how much information to share with patients and how to explain it, Schiff said. There are also concerns that in tracking their samples, patients could tell others what they learned before researchers are ready to publicly release this information. However, Bogdan, the vice president of the HIMSS nonprofit, believes only a minimal study identifier would be stored in an NFT, not patient data, research results or any type of proprietary trial information.
Some patients may be confused by blockchain and reluctant to embrace it. “The complexity of NFTs may prevent the average citizen from capitalizing on their potential or vendors willing to participate in the blockchain network,” Bogdan said. “Blockchain technology is also quite costly in terms of computational power and energy consumption, contributing to greenhouse gas emissions and climate change.”
In addition, this nascent, groundbreaking technology is immature and vulnerable to data security flaws, disputes over intellectual property rights and privacy issues, though it does offer baseline protections to maintain confidentiality. To truly make a difference, blockchain must enable broad consent from patients, not just de-identification, said Robyn Shapiro, a bioethicist and founding attorney at Health Sciences Law Group near Milwaukee.
The Henrietta Lacks story is a prime example, Shapiro noted. During her treatment for cervical cancer at Johns Hopkins, Lacks’s tissue was de-identified (albeit not entirely, because her cell line, HeLa, bore her initials). After her death, those cells were replicated and distributed for important and lucrative research and product development purposes without her knowledge or consent.
Nonetheless, Shapiro thinks that the initiative by the University of Pittsburgh and Johns Hopkins has potential to solve some ethical challenges involved in research use of biospecimens. “Compared to the system that allowed Lacks’s cells to be used without her permission, Shapiro said, “blockchain technology using nonfungible tokens that allow patients to follow their samples may enhance transparency, accountability and respect for persons who contribute their tissue and clinical data for research.”
Read more about laws that have prevented people from the rights to their own cells.